- Conditions
- Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
- Interventions
- Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Radiation · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 898 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2035
- U.S. locations
- 846
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1177–1200
of 1,306
matching trials from the local directory fallback.
- Conditions
- Renal Cell Carcinoma
- Interventions
- Everolimus, Lenvatinib, Pembrolizumab, Sunitinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,069 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 35
- States / cities
- Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
- Conditions
- Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Interventions
- Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
- Conditions
- Breast Cancer
- Interventions
- Alpelisib, Fulvestrant, Gedatolisib, Palbociclib
- Drug
- Lead sponsor
- Celcuity Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 62 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Abemaciclib, Erlotinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 54
- States / cities
- Fayetteville, Arkansas • Jonesboro, Arkansas • Duarte, California + 39 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Pirtobrutinib, Rituximab, Venetoclax
- Drug
- Lead sponsor
- Loxo Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Orange, California + 32 more
- Conditions
- Peripheral Nerve Injuries
- Interventions
- Autogenous Nerve Graft, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization, Nerve Tube Conduit, Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.
- Other · Procedure · Device
- Lead sponsor
- Axogen Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 3,126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2028
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Orange, California • San Francisco, California + 33 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- CCNU, adjuvant temozolomide (TMZ), concomitant temozolomide (TMZ), procarbazine, radiotherapy, vincristine
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 271
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 185 more
- Conditions
- Myelofibrosis (MF)
- Interventions
- Best Available Therapy (BAT), Navitoclax, Ruxolitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Springdale, Arkansas • Duarte, California + 34 more
- Conditions
- Aggressive B-cell Lymphoma With Secondary Involvement of the CNS, Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
- Interventions
- 18f-FDG-PET, Acetaminophen, Bone marrow aspiration/biopsy, CT Scan (chest, abdomen, and pelvis), Diphenhydramine, EKG, Ibrutinib, Lenalidomide, Lumbar puncture/Ommaya tap, MRI, Obinutuzumab, PET, Peg-filgrastim, Prednisone, Venetoclax
- Diagnostic Test · Drug · Combination Product + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Amputation
- Interventions
- Needs-based intervention (physical, psychological, or both)
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 680
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
- Conditions
- Graft Versus Host Disease, Hematologic Neoplasms
- Interventions
- Busulfan, Cyclophosphamide, Fludarabine, Mycophenolate Mofetil, Sirolimus
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- AAV BBP-631
- Biological
- Lead sponsor
- Adrenas Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Other · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2036
- U.S. locations
- 1613
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
- Conditions
- Sjogren's Syndrome
- Interventions
- Placebo, tofacitinib
- Other · Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Ovarian Cancer, BRCA Mutation, Complete Response, FIGO Stage III-IV, First Line Platinum Chemotherapy, Newly Diagnosed, Partial Response
- Interventions
- Olaparib 300mg tablets
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2028
- U.S. locations
- 81
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
- Conditions
- Breast Cancer, Non-small Cell Lung Carcinoma
- Interventions
- Pembrolizumab, Trastuzumab deruxtecan (DS-8201a)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 10
- States / cities
- San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
- Conditions
- Acinetobacter Baumannii Infection, Antimicrobial Drug Resistance, Carbapenem Resistant Bacterial Infection
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
- Procedure · Biological · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 70
- States / cities
- Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
- Conditions
- Radiology Information Systems
- Interventions
- Not listed
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 1 Year to 100 Years
- Enrollment
- 144,625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Recurrent, High Grade Ovarian Serous Adenocarcinoma, Mesothelioma, Mesothelioma Peritoneum, Mesothelioma, Malignant, Mesothelioma; Pleura, Mesotheliomas Pleural, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Ovarian Cancer
- Interventions
- Ipilimumab, Nivolumab, cyclophosphamide, fludarabine, gavo-cel
- Drug · Biological
- Lead sponsor
- TCR2 Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 10
- States / cities
- San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ABBV-453, Daratumumab, Dexamethasone, Lenalidomide
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 12
- States / cities
- Stanford, California • Miami, Florida • New Orleans, Louisiana + 9 more
- Conditions
- Polycythemia Vera
- Interventions
- P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
- Drug
- Lead sponsor
- PharmaEssentia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Jacksonville, Florida • Fort Wayne, Indiana • Westwood, Kansas + 14 more